Patents Represented by Attorney Joseph W. Bulock
  • Patent number: 8338455
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as VEGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: December 25, 2012
    Assignee: Amgen Inc.
    Inventors: Yuan Cheng, Deborah Choquette, Jean-Christophe Harmange, Andrew Tasker
  • Patent number: 8247556
    Abstract: The invention encompasses a method for preparing 6-susbtituted-7-aza-indoles.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: August 21, 2012
    Assignee: Amgen Inc.
    Inventor: Thomas Storz
  • Patent number: 8222251
    Abstract: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: July 17, 2012
    Assignee: Amgen Inc.
    Inventors: Jacob Kaizerman, Brian Lucas, Dustin McMinn, Robert Zamboni
  • Patent number: 8178557
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: May 15, 2012
    Assignee: Amgen Inc.
    Inventors: Michele Potashman, Tae-Seong Kim, Steven Bellon, Shon Booker, Yuan Cheng, Joseph L. Kim, Andrew Tasker, Ning Xi, Shimin Xu, Jean-Christophe Harmange, George Borg, Matthew Weiss, Brian L. Hodous, Russell Graceffa, William H. Buckner, Craig E. Masse, Deborah Choquette, Matthew W. Martin, Julie Germain, Lucian V. DiPietro, Stuart C. Chaffee, Joseph J. Nunes, John L. Buchanan, David C. McGowan, Douglas A. Whittington, Gregory J. Habgood, Vinod F. Patel, Daniel La
  • Patent number: 8153633
    Abstract: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.
    Type: Grant
    Filed: June 23, 2008
    Date of Patent: April 10, 2012
    Assignee: Amgen Inc.
    Inventors: Richard J. Austin, Jacob Kaizerman, Brian Lucas, Dustin L. McMinn, Jay Powers
  • Patent number: 8058445
    Abstract: Selected pyridine carboxamide compounds of Formula XI are effective for treatment of diseases and other maladies or conditions involving, cancer and the like.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: November 15, 2011
    Assignee: Amgen Inc.
    Inventor: Andrew Tasker
  • Patent number: 7989631
    Abstract: The anti-angiogenic drug AMG 706 is provided in the mono-phosphate hydrate form. Also provided is AMG 706 drug substance wherein the AMG 706 is present, in at least a detectable amount, as AMG 706 phosphate dihydrate. Also provided are processes for preparing AMG 706 phosphate dihydrate, AMG 706 drug substance of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with an anti-angiogenic is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: August 2, 2011
    Assignee: Amgen Inc.
    Inventors: Gonzalo Alva, Seshadri Neervannan
  • Patent number: 7858785
    Abstract: The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: December 28, 2010
    Assignee: Amgen Inc.
    Inventors: Adrian Leonard Smith, Paul Edward Brennan, Fenel F. Fils, Gang Liu, Nick A. Paras, Daniel Martin Retz, Elizabeth Rainbeau
  • Patent number: 7795254
    Abstract: Selected benzomorpholine compounds, including 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(5 -methyl-3-isoxazolyl)-2,3-dihydro-4H-1,4-benzoxazine-4-carboxamide, are effective for prophylaxis and treatment of diseases, such as VEGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: October 28, 2008
    Date of Patent: September 14, 2010
    Assignee: Amgen Inc.
    Inventors: Jean-Christophe Harmange, Matthew W. Martin, Yohannes Teffera, Raju Subramanian, Ryan White, Roger Zanon, Jay Larrow, Joseph F. Payack, Mina Dilmeghani Seran
  • Patent number: 7786132
    Abstract: The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: August 31, 2010
    Assignee: Amgen Inc.
    Inventors: Adrian Leonard Smith, Paul Edward Brennan, Frenel Fils DeMorin, Gang Liu, Nick A. Paras, Daniel Martin Retz, Elizabeth Rainbeau
  • Patent number: 7687643
    Abstract: Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: March 30, 2010
    Assignee: Amgen Inc.
    Inventors: Andrew Tasker, Shawn Eisenberg, Yuelie Lu
  • Patent number: 7560460
    Abstract: Selected substituted piperazine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: April 27, 2005
    Date of Patent: July 14, 2009
    Assignee: Amgen Inc.
    Inventors: Christopher H. Fotsch, Michael G. Kelly, Mark H. Norman, Ning Xi, Shimin Xu
  • Patent number: 7531553
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: May 12, 2009
    Assignee: Amgen Inc.
    Inventors: Lucian V. Di Pietro, Jean-Christophe Harmange, Benny C. Askew, Jr., Daniel Elbaum, Julie Germain, Gregory J. Habgood, Joseph L. Kim, Vinod F. Patel, Michele Potashman, Simon van der Plas
  • Patent number: 7514564
    Abstract: Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: April 7, 2009
    Assignee: Amgen Inc.
    Inventors: Guoqing Chen, Jeffrey Adams, Jean Bemis, Lucian Di Pietro, Celia Dominguez, Daniel Elbaum, Julie Germain, Qi Huang, Joseph L. Kim, Xiaohu Ouyang, Vinod F. Patel, Leon M. Smith, Andrew Tasker, Ning Xi, Shimin Xu, Chester Chenguang Yuan, Michael Croghan, Tae-Seong Kim
  • Patent number: 7435823
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: October 14, 2008
    Assignee: Amgen Inc.
    Inventors: Michele Potashman, Tae-Seong Kim, Steven Bellon, Shon Booker, Yuan Cheng, Joseph L. Kim, Andrew Tasker, Ning Xi, Shimin Xu, Jean-Christophe Harmange, George Borg, Matthew Weiss, Brian L. Hodous, Russell Graceffa, William H. Buckner, Craig E. Masse, Deborah Choquette, Matthew W. Martin, Julie Germain, Lucian V. DiPietro, Stuart C. Chaffee, Joseph J. Nunes, John L. Buchanan, Gregory J. Habgood, David C. McGowan, Douglas A. Whittington, Daniel La, Vinod F. Patel
  • Patent number: 7390820
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: August 24, 2004
    Date of Patent: June 24, 2008
    Assignee: Amgen Inc.
    Inventor: Christopher Tegley
  • Patent number: 7320992
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: August 24, 2004
    Date of Patent: January 22, 2008
    Assignee: Amgen Inc.
    Inventors: Christopher Tegley, Jeffrey A. Adams, Benny C. Askew, Jr., Michael Croghan, Daniel Elbaum, Julie Germain, Gregory J. Habgood, Scott Harried, Aiwen Li, Nobuko Nishimura, Rana Nomak, Andrew Tasker, Kevin Yang
  • Patent number: 7307088
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: December 11, 2007
    Assignee: Amgen Inc.
    Inventors: Qi Huang, Guoqing Chen, Aiwen Li, Babak Riahi, Andrew Tasker, Kevin Yang, Chester Chenguang Yuan
  • Patent number: 7282504
    Abstract: The invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting kinase activity, and methods for treating disease or disease symptoms.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: October 16, 2007
    Assignee: Amgen Inc.
    Inventors: David M. Armistead, Jean E Bemis, Lucian V DiPietro, Stephanie D. Geuns-Meyer, Gregory J. Habgood, Joseph L. Kim, Joseph J. Nunes, Vinod F. Patel, Leticia M. Toledo-Sherman
  • Patent number: 7115617
    Abstract: The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: October 3, 2006
    Assignee: Amgen Inc.
    Inventors: John L. Buchanan, Stuart Chaffee, Jean-Christophe Harmange, Perry M. Novak, Xiaotian Zhu